Maternal obesity, interpregnancy weight changes and congenital heart defects in the offspring

Gitte Hedermann, MD*[1,2,3]; Ida N Thagaard, MD, PhD[1,4]; Paula L Hedley, PhD, MPH[1]; Lone Krebs, MD, DMSc[5,6];

Christian Munch Hagen, MSc[1]; Thorkild IA Sørensen, MD, DMSc[7,8]; Michael Christiansen, MD, FRCPath[1,9]; Charlotte

Kvist Ekelund, MD, PhD[6,10]

[1] Department for Congenital Disorders, Danish National Biobank and Biomarkers, Statens Serum Institut, Copenhagen,

Denmark

[2] Department of Obstetrics and Gynecology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark

[3] Department of Obstetrics and Gynecology, Slagelse Hospital, Denmark

[4] Department of Obstetrics and Gynecology, Nordsjaellands Hospital, Denmark

[5] Department of Obstetrics and Gynecology, Copenhagen University Hospital, Amager and Hvidovre Hospital,

Copenhagen, Denmark

[6] Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark

[7] Department of Public Health, Section of Epidemiology, University of Copenhagen, Copenhagen, Denmark

[8] The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences,

University of Copenhagen, Copenhagen, Denmark

[9] Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark

[10] Center of Fetal Medicine, Department of Obstetrics, Copenhagen University Hospital, Rigshospitalet, Copenhagen,

Denmark

25 **Précis**

26 Maternal BMI is positively associated with risk of congenital heart defect in the offspring but weight change between

27 pregnancies does not influence the risk significantly.

Abstract

Objective: To evaluate the association between maternal obesity and congenital heart defects (CHDs) in the offspring when including live births, stillbirths and terminated pregnancies and to investigate if interpregnancy weight change between the first and second pregnancy influences risk of fetal CHDs.

Methods: A nationwide cohort study of all singleton pregnancies in Denmark from 2008 to 2018. All data on maternal and offspring characteristics were retrieved from the Danish Fetal Medicine Database including prenatal diagnoses. CHDs and severe CHDs were defined according to European Surveillance of Congenital Anomalies' definitions. Children or fetuses with chromosomal aberrations were excluded. Relative risks (RRs) were calculated using log-linear Poisson models.

Results: Of the 547 178 pregnancies included in the cohort, 5 498 had CHDs (1.00%). Risk of CHDs became gradually higher with higher maternal body mass index (BMI); for BMI 30-34.9, adjusted relative risk (aRR) = 1.23, 95% confidence interval (CI) 1.12-1.36, for BMI 35-39.9, aRR = 1.26, 95% CI 1.09-1.46 and for BMI ≥ 40, aRR = 1.81, 95% CI 1.50-2.15. Data was adjusted for maternal age, smoking status and birth year. The same pattern was seen for the subgroup of severe CHDs. Among the atrioventricular septal defects (n = 245), a particularly strong association with maternal BMI ≥ 40 was seen, aRR = 4.19, 95% CI 2.13-7.42. Interpregnancy BMI change was positively, albeit not significanty, associated with risk of CHDs in the second pregnancy when adjusting for maternal age and BMI, with an aRR = 1.27, 95% CI 0.96-1.64 among persons with a BMI increase of ≥ 4 kg/m^2 was found.

Conclusion: When including both pre-and post-natally diagnosed CHDs, this study showed a dose-response association between maternal BMI and risk of CHDs in the offspring. However, only a non-significant trend was seen between interpregnancy BMI changes and risk of CHDs.

Introduction

Obesity among women of reproductive age has been increasing over the last three decades.(1) Centers for Disease Control and Prevention estimated that 40% of women aged 20-39 years old in the United States were obese (body mass index [BMI] ≥ 30 kg/m^2) in 2017-2018.(2) Maternal obesity is a risk factor for adverse pregnancy outcomes as well as for long-term health consequences for both the mother and child.(3, 4) Furthermore, maternal obesity is positively associated with risk of having a child with congenital malformations.(5)

Congenital heart defects (CHDs) remain the leading cause of infant death from congenital malformations in the United States.(6) Believed to be the most common congenital malformation, CHDs have a global prevalence of nine per 1000 live births with geographical differences.(7) The causes of CHDs are unknown in most cases, but are associated with maternal chronic conditions, viral infections and fetal exposures to teratogenic drugs.(8-10) With improvements in genetic and genomic analytical techniques an increasing number of genetic associations/causes have been identified.(11) These findings may contribute to explain the high sibling- and recurrence risk of CHDs reported from large register studies.(12)

The association between maternal obesity and congenital malformations has been reported to include CHDs. However, none of the large studies have included the considerable proportion of CHDs that are identified and terminated in pregnancy. During the last two decades, the prenatal identification of CHDs have increased dramatically, consequently, an analysis of the association between maternal risk factors and CHDs should include data on prenatally identified cases. Meta-analyses suggest a moderate association between maternal obesity (BMI ≥ 30 kg/m^2) and CHDs in the offspring with an odds ratio (OR) = 1.2 (95% confidence interval [CI] 1.1–1.2)(13) or an OR = 1.3 (95% CI 1.2–1.4).(14) A recent systematic review on the topic demonstrated great heterogeneity among the studies with respect to design, exposure definition, outcome definition, choice of covariates, and only populations of Northern European or Chinese descent were examined to a reasonable extent.(15)

Some studies have found an association between maternal interpregnancy BMI changes and adverse pregnancy- and perinatal outcomes that were linearly related to the amount of weight gain.(16, 17) So far, a few small studies suggest that this might be relevant for certain congenital malformations (spina bifida, gastroschisis and oral cleft),(16, 18-20) however, no data is available in these studies for fetal CHDs. It is of great importance to identify any modifiable risk

factors for CHDs. If weight gain, defined as interpregnancy BMI change, is associated with CHDs, this could be added

to the justification of preventive initiatives as to stress weight stability, and for some women weight loss.

This study aims to assess the risk of having a child with CHDs, severe CHDs or five of the most frequently identified

subtypes of CHDs in pregnant women according to early-pregnancy BMI. The study population comprises all CHDs

found among live births, stillbirths, abortions and terminated pregnancies in Denmark. Furthermore, investigate if

changes in maternal BMI from the beginning of the first pregnancy to the beginning of the second pregnancy were

associated with risk of CHDs in the second pregnancy.

Methods

This cohort study was performed on prospectively collected data retrieved from a nationwide cohort based on The

Danish Fetal Medicine Database.(21) The Danish Fetal Medicine Database includes data on pregnancies with prenatal

screening results from all obstetric and gynecological departments in Denmark from January 1, 2008.(21) All women in

Denmark are offered a first trimester screening for chromosomal abnormalities and a second trimester anomaly scan,

for which the uptake rate is high; 95% of pregnant women participate. The database does not include data on

outcomes of pregnancies before the first trimester scan. The primary source of information is the local fetal medicine

databases used nationwide. The databases include data on maternal characteristics including weight and height, data

from ultrasound examinations and pregnancy outcomes.(21) Furthermore, the database includes data from other

Danish registers: the Danish Cytogenetic Central Register,(22) the Danish National Patient Register,(23) and the Danish

Medical Birth Register.(24) All Danish residents are assigned a unique personal identification number enabling linkage

of data between national registers and other data sources.(25) The Danish Fetal Medicine database is updated once a

year with information on postnatal diagnosed congenital malformations and karyotypes.(21) The International

Classification of Diseases, 10th revision code system (ICD-10) is used to code malformations in the fetus and in the

infant.(21)

The cohort included singleton pregnancies in Denmark with an estimated due date, from ultrasound scan, between

June 1, 2008 and June 1, 2018. Pregnancies with a fetus or child with a chromosomal aberration were excluded from

the cohort. Only pregnant women with a registered early-pregnancy weight and a height from 120 through 200 cm

were included. Maternal BMI was calculated as weight in kilograms divided by the square of the height in meters

(kg/m^2) and BMI values are reported in that unit. Extreme observations defined as BMI < 12 and BMI > 60 were

excluded.

We identified fetuses and infants with CHDs (Table S1) by using either the prenatal or/and the postnatal diagnoses.

The CHD diagnoses were defined by the European Surveillance of Congenital Anomalies (EUROCAT)(26) (Table S1) and

severe CHDs (EUROCAT, Table S1). Severe CHDs include the following 17 diagnoses: truncus arteriosus, double outlet

right ventricle, transposition of the great arteries (TGA), univentricular heart (UVH), atrioventricular septum defect

(AVSD), Tetralogy of Fallot (ToF), pulmonary atresia, tricuspid valve stenosis, Ebstein's anomaly, hypoplastic right

heart syndrome, aortic valve stenosis, mitral valve stenosis, mitral insufficiency, hypoplastic left heart syndrome,

coarctation of the aorta (CoA), aortic atresia, and total anomalous pulmonary venous return. Irrespective of the

number of CHD diagnoses in a particular patient, the patient was only registered once as having CHDs. Furthermore,

offspring with five of the most frequently identified, perinatally and neonatally, subtypes of severe CHDs were

identified (Table S2). These were ranked as defined by Lytzen et al.(27) with the most severe first (UVH > TGA > AVSD

> CoA > ToF). If offspring had combinations of these subtypes, they were only registered once with the most severe

diagnosis. ICD-10 codes for severe CHDs have been validated against hospital records with very good agreement in the

Danish National Patient Register.(28) Prenatal diagnoses of 12 severe CHDs have been shown to have a very high

diagnostic precision.(29)

For the calculations of interpregnancy BMI changes, a sub-cohort including women with first and second pregnancies

and more than 50 weeks between estimated due dates was compiled. Maternal height was defined as the height

registered in the first pregnancy. Interpregnancy BMI changes were calculated as the difference between BMI at the

beginning of the first and BMI at the beginning of the second pregnancy. Differences were categorized into six groups

< -2; -2 to < -1; -1 to < 1; 1 to < 2; 2 to < 4; and ≥4 BMI units. The category -1 to < 1 was defined as stable weight and

used as reference.

Associations between maternal BMI and offspring risk of CHDs were calculated as risk ratios (RRs) with 95% CI using

log-linear Poisson regression models. The models were adjusted for maternal age (<20, 20–24, 25–29, 30–34, 35–39,

≥40), maternal smoking status (yes/no/stopped), and year of estimated due date (1-year groups). Associations

between interpregnancy BMI changes and risk of CHDs were calculated as RRs with 95% CI using log-linear Poisson

regression models. Maternal BMI in first pregnancy and maternal age at second pregnancy were considered possible

confounders and were adjusted for in the multivariate model. Statistical analyses were run in R version 4.2.1. Statens

Serum Institut has approval from the Danish Data Protection Agency to conduct register-based studies, and the

project has been approved (journal no. 19/03354 and 20/09279).

Results

The study cohort consisted of 547 178 singleton pregnancies with estimated due dates between June 1, 2008 and June

1, 2018 when pregnancies with chromosomal aberrations and missing data were excluded as detailed in Figure 1. A

total of 5 498 (1.00%) offsprings had CHDs. Of these 1 227 were defined as severe CHDs (0.22%). Clinical and

demographic data are available in Table 1. Information on parity was not registered and therefore missing in the

dataset from 2008-2011 corresponding to 25% of the pregnancies. The study cohort comprised 534 478 live births

(97.7%), 1 623 stillbirths (0.3%), 5 073 abortions or terminated pregnancies (0.9%), and 6 004 pregnancies with

missing outcomes (1.1%). In total, 35% of the women had an early-pregnancy BMI ≥ 25, and 13% were obese (BMI ≥

30). The distribution of maternal BMI among the different groups and covariates can be seen in Table 1.

Maternal overweight was associated significantly with higher risk of CHDs in the offspring increasing with higher

maternal BMI (aRR = 1.17-1.81; Table 2). Similar results were seen for maternal BMI and severe CHDs (aRR = 1.20-

1.85; Table 2). A slightly higher risk of CHDs, when only including live births compared to all pregnancies, was seen for

maternal BMI ≥ 30 (aRR 1.24-1.87; data available in Table S3).

The proportion of CHD cases with one of the five specific CHD diagnoses were as follows: univentricular heart (UVH;

4.4%), transposition of the great arteries (TGA; 3.2%), atrioventricular septum defect (AVSD; 4.5%), coarctation of the

aorta (CoA; 4.6%), and Tetralogy of Fallot (ToF; 2.3%). The association between maternal BMI and these specific five

CHD diagnoses are shown in Figure 2. No significant associations were seen for UVH, TGA, CoA and ToF. However,

maternal BMI ≥ 30 was associated with a significantly higher risk of AVSD in the offspring (Figure 2).

The sub-cohort included 107 627 women who had a first and second consecutive singleton pregnancies between June

1, 2008 and June 1, 2018 (Table 3). Of these, 998 had an offspring with CHDs in their second pregnancy. The

prevalence of CHDs in the second pregnancy became higher with increased weight gain between pregnancies (0.8% to

1.3%). Mean BMI in first pregnancy was 24.9 vs. 25.8 in second pregnancy. Increase in maternal BMI between

pregnancies were significantly associated with higher risk of CHDs in second pregnancy. However, when adjusted for

maternal age and maternal BMI in the first pregnancy, only a trend remained towards higher risks of any CHDs

with weight gain between pregnancies (Table 3).

Discussion

This large prospective nationwide cohort included 547 178 live births, stillbirths, abortions and terminated

pregnancies in Denmark from 2008 to 2018 and showed that maternal overweight and obesity were significantly

associated with a moderately higher risk of CHDs (aRR = 1.17-1.81) and severe CHDs (aRR = 1.20-1.85) in the offspring

compared to women with a BMI in the normal range (BMI 18.5-24.9). However, results from five specific subtypes of

CHDs (univentricular heart, UVH; transposition of the great arteries, TGA; atrioventricular septum defect, AVSD;

coarctation of the aorta CoA; and Tetralogy of Fallot, ToF) showed no significant association with maternal BMI except

for AVSD, which was associated with increasing risks for maternal BMI ≥ 30 (BMI 30 to ≥ 40: aRR = 1.65-4.19).

Interpregnancy BMI gain between first and second pregnancies showed a trend towards higher risks of CHDs in

second pregnancies preceded by a substantial gain in BMI but this was not significant when data was adjusted for

maternal BMI in first pregnancy and maternal age in second pregnancy.

An association between maternal obesity and risk of CHDs has been found in a recent systematic review including 32

studies with millions of pregnancies and hypothesized to be linked to insulin resistance.(15) The present study is

unique in that it includes live births, stillbirths, abortions and terminated pregnancies. Two minor regional case-

control studies have also included all pregnancies, but resulted in inconsistent results.(30, 31) Thus, an American study

found a significant association between maternal obesity (BMI ≥ 30) and CHDs in the offspring (OR = 2.0, 95% CI 1.2–

3.4),(31) whereas an English study could not confirm such an association.(30) Most other studies have been limited to

live births.(15, 32) A large nationwide Swedish study with two million live born children has recently found a positive

association between high maternal BMI and CHDs (BMI 30-34.9: OR = 1.2, 95% CI 1.2–1.3; BMI ≥ 40: OR = 1.6, 95% CI

1.4–1.8).(32) Restricting our analysis to live births (Table S3), we found significant associations of a similar magnitude

between maternal BMI ≥ 25 and CHDs.

Prenatal detection rates of congenital malformations decreases with increasing maternal BMI since image quality is

lower in women with obesity.(33, 34) Consequently, studies only including live births could be biased towards a higher

postnatal prevalence of CHDs in obese women if severe fetal CHDs were not diagnosed and possibly terminated

during pregnancy (Table 1). Thus, this phenomenon may at least partly explain a positive association between high

BMI and prevalence of CHDs in live borns.(5) Prenatal detection rates of CHDs have improved substantially in the last

decades, and in countries with prenatal screening with high detection rate of CHDs as in Denmark,(29) it is more

important to include terminated pregnancies in prevalence and association studies as the rate of terminated

pregnanciess with the most severe CHDs likely will be higher as seen in Table 1.

Of the severe CHD subtypes analyzed, only AVSD showed a significant and increasing association with higher maternal

BMI. The other subtypes showed a trend, albeit, non-significant (Figure 2). Persson et al. found a non-significant trend

between maternal BMI and AVSD in women with BMI ≥ 30.(5) This might be due to the fact that when Persson et al.

calculated risk of AVSD, all children with CHDs other than AVSD and without CHDs were kept in the denominator and

the results could be biased towards the null.(5) A Canadian study with 2.3 million pregnancies found an aOR = 1.43,

95% CI 0.70-2.91 for AVSD and maternal obesity but information on BMI was not given.(9) A study from Florida

including 1.1 million pregnancies reported an aOR = 1.55, 95% CI 1.09-2.22 when maternal BMI ≥ 30, however, when

dividing maternal BMI into subgroups only a trend remained.(35) Another American study on AVSD found an adjusted

prevalence ratio = 1.5, 95% CI 0.9-2.4 when maternal BMI ≥ 30.(36) As maternal obesity, pregestational diabetes and

preeclampsia all have been associated with CHDs and insulin resistance,(15) it is interesting that AVSD is the CHD

subtype that exhibited the most pronounced association with preeclampsia in a recent Danish study.(37)

The etiology of CHDs is complex with a genetic etiology, transcription factor, ciliary, and growth factor genes,

identifiable in up to 30% of the cases and a mixture of environmental causes.(38-42) In this study, we have excluded

CHD cases with identified chromosomal variants that might confound the association study. We have not had access

to data on prepregnancy diabetes, which is associated with both CHDs and obesity.(43) It constitutes a confounder;

however, as the prevalence of prepregnancy diabetes is 0.36% and the RR for CHDs is four,(43) it cannot dramatically

confound our study.

An interesting confounder might be the genetic diversity of CHDs. Recently, it has become clear that genes involved in

the structure and function of cilia are also involved in cardiogenesis.(11, 44) Furthermore, a forward genetic screen in

mice revealed a major significance of ciliary genes in CHD phenotypes.(45) Due to the ubiquitous involvement of cilia

in developmental processes ciliopathies frequently present as syndromes.(46) Genetic models in mice have shown

that many genes involved in ciliary function are involved in obesity.(47) Both organism-wide and neuron-specific loss

of cilia cause obesity in mouse models.(48) Furthermore, some human ciliopathies express obesity as part of the

syndrome, e.g. Bardet-Biedl, Alstrom and Carpenter syndromes.(11, 47, 49, 50) As we have not carefully examined for

genetic variants, i.e. screened for variants in ciliary genes, we cannot exclude that ciliary gene variants might

contribute to the association between obesity and CHDs. In order to better understand the causation of CHDs and its

potential association with obesity and metabolic disorders,(15) more detailed studies with deep phenotyping and

extensive genetic investigations should be performed.

The investigations of the association between interpregnancy weight changes and risk of fetal CHDs are sparse.(16) A

few studies have looked at other congenital malformations and found a RR = 2.3 for isolated cleft palate when

maternal BMI increased ≥ 3 units,(20) a positive association between spina bifida and interpregnancy BMI gain when

assessed as a continuous variable,(18) and a significant decrease in OR = 0.62 (95% CI 0.42-0.94) for gastroschisis

when maternal BMI increased with ≥ 3 units.(19) We examined the interpregnancy weight changes between the first

and second pregnancies in a 107 627 women and could not establish a significant association between increase or

decrease in prepregnancy weight and risk of CHDs in the second pregnancy (Table 3). Major interpregnancy changes in

BMI could be caused by specific intercurrent maternal pathological conditions not part of the classical metabolic

syndrome. Such conditions have not been excluded in the present study. However, our results suggest that it is not

justifiable to recommend interpregnancy weight reduction with the aim of reducing CHD risk.

The strength of this study is the large size of the cohort and prospectively, nationwide data collection including

prenatal information. Some limitation must be considered. The database did not include data on pregestational

diabetes, which is known to be strongly associated with CHDs.(15, 43). Nor did the data include information on

maternal infections or teratogenic medicine intake in pregnancy that have been associated with higher risk of

CHDs.(8) Since the study draws conclusions from register data, there is a risk of reporting bias and all CHD diagnoses

are not validated against hospital records.

References

1. Poston L, Caleyachetty R, Cnattingius S, Corvalan C, Uauy R, Herring S, et al. Preconceptional and maternal obesity:

epidemiology and health consequences. Lancet Diabetes Endocrinol 2016 Dec;4(12):1025-36.

2. Hales CMC, M. D.; Fryar, C. D.;Ogden, C. L. Prevalence of Obesity and Severe Obesity Among Adults: United States,

2017–2018. 2020 [cited; No. 360:[Available from: https://www.cdc.gov/nchs/products/databriefs/db360.htm

3. Godfrey KM, Reynolds RM, Prescott SL, Nyirenda M, Jaddoe VW, Eriksson JG, et al. Influence of maternal obesity on

the long-term health of offspring. Lancet Diabetes Endocrinol 2017 Jan;5(1):53-64.

4. Catalano PM, Shankar K. Obesity and pregnancy: mechanisms of short term and long term adverse consequences

for mother and child. BMJ 2017 Feb 8;356:j1.

5. Persson M, Cnattingius S, Villamor E, Soderling J, Pasternak B, Stephansson O, et al. Risk of major congenital

malformations in relation to maternal overweight and obesity severity: cohort study of 1.2 million singletons. BMJ

2017 Jun 14;357:j2563.

6. Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, et al. Heart Disease and Stroke Statistics-

2018 Update: A Report From the American Heart Association. Circulation 2018 Mar 20;137(12):e67-e492.

7. Liu Y, Chen S, Zuhlke L, Black GC, Choy MK, Li N, et al. Global birth prevalence of congenital heart defects 1970-

2017: updated systematic review and meta-analysis of 260 studies. Int J Epidemiol 2019 Apr 1;48(2):455-63.

8. Jenkins KJ, Correa A, Feinstein JA, Botto L, Britt AE, Daniels SR, et al. Noninherited risk factors and congenital

cardiovascular defects: current knowledge: a scientific statement from the American Heart Association Council on

Cardiovascular Disease in the Young: endorsed by the American Academy of Pediatrics. Circulation 2007 Jun

12;115(23):2995-3014.

9. Liu S, Joseph KS, Lisonkova S, Rouleau J, Van den Hof M, Sauve R, et al. Association between maternal chronic

conditions and congenital heart defects: a population-based cohort study. Circulation 2013 Aug 6;128(6):583-9.

10. Ye Z, Wang L, Yang T, Chen L, Wang T, Chen L, et al. Maternal Viral Infection and Risk of Fetal Congenital Heart

Diseases: A Meta-Analysis of Observational Studies. J Am Heart Assoc 2019 May 7;8(9):e011264.

11. Pierpont ME, Brueckner M, Chung WK, Garg V, Lacro RV, McGuire AL, et al. Genetic Basis for Congenital Heart

Disease: Revisited: A Scientific Statement From the American Heart Association. Circulation 2018 Nov

20;138(21):e653-e711.

12. Brodwall K, Greve G, Leirgul E, Tell GS, Vollset SE, Oyen N. Recurrence of congenital heart defects among siblings-a

nationwide study. Am J Med Genet A 2017 Jun;173(6):1575-85.

13. Zhu Y, Chen Y, Feng Y, Yu D, Mo X. Association between maternal body mass index and congenital heart defects in

infants: A meta-analysis. Congenit Heart Dis 2018 Mar;13(2):271-81.

14. Zheng Z, Yang T, Chen L, Wang L, Zhang S, Wang T, et al. Increased maternal Body Mass Index is associated with

congenital heart defects: An updated meta-analysis of observational studies. Int J Cardiol 2018 Dec 15;273:112-20.

15. Hedermann G, Hedley PL, Thagaard IN, Krebs L, Ekelund CK, Sorensen TIA, et al. Maternal obesity and metabolic

disorders associate with congenital heart defects in the offspring: A systematic review. PLoS ONE

2021;16(5):e0252343.

16. Bogaerts A, Van den Bergh BRH, Ameye L, Witters I, Martens E, Timmerman D, et al. Interpregnancy weight change

and risk for adverse perinatal outcome. Obstet Gynecol 2013 Nov;122(5):999-1009.

17. Villamor E, Cnattingius S. Interpregnancy weight change and risk of adverse pregnancy outcomes: a population-

based study. The Lancet 2006;368(9542):1164-70.

18. Benjamin RH, Ethen MK, Canfield MA, Hua F, Mitchell LE. Association of interpregnancy change in body mass index

and spina bifida. Birth Defects Res 2019 Nov 1;111(18):1389-98.

19. Benjamin RH, Ethen MK, Canfield MA, Mitchell LE. Change in prepregnancy body mass index and gastroschisis. Ann

Epidemiol 2020 Jan;41:21-7.

20. Villamor E, Sparen P, Cnattingius S. Risk of oral clefts in relation to prepregnancy weight change and

interpregnancy interval. Am J Epidemiol 2008 Jun 1;167(11):1305-11.

21. Ekelund CK, Kopp TI, Tabor A, Petersen OB. The Danish Fetal Medicine database. Clin Epidemiol 2016;8:479-83.

22. Videbech P, Nielsen J. Electronic data processing in the Danish cytogenetic central register and EDP problems of

registers in general. Clin Genet 1979 Feb;15(2):137-46.

23. Lynge E, Sandegaard JL, Rebolj M. The Danish National Patient Register. Scand J Public Health 2011 Jul;39(7

Suppl):30-3.

24. Knudsen LB, Olsen J. The Danish Medical Birth Registry. Dan Med Bull 1998 Jun;45(3):320-3.

25. Pedersen CB, Gotzsche H, Moller JO, Mortensen PB. The Danish Civil Registration System. A cohort of eight million

persons. Dan Med Bull 2006 Nov;53(4):441-9.

26. EUROCAT. European network of population-based registries for the epidemiological surveillance of congenital

anomalies.   [cited; Available from: https://eu-rd-platform.jrc.ec.europa.eu/eurocat_en

27. Lytzen R, Vejlstrup N, Bjerre J, Petersen OB, Leenskjold S, Dodd JK, et al. Live-Born Major Congenital Heart Disease

in Denmark: Incidence, Detection Rate, and Termination of Pregnancy Rate From 1996 to 2013. JAMA Cardiology

2018;3(9):829-37.

28. Agergaard P, Hebert A, Bjerre J, Sorensen KM, Olesen C, Ostergaard JR. Children diagnosed with congenital cardiac

malformations at the national university departments of pediatric cardiology: positive predictive values of data in the

Danish National Patient Registry. Clin Epidemiol 2011;3:61-6.

29. Vedel C, Tabor A, Jorgensen FS, Rode L, Sundberg K, Vejlstrup N, et al. Prenatal detection rate of major congenital

heart defects in Copenhagen from 2015 to 2018. Ultrasound Obstet Gynecol 2021 Aug;58(2):324-5.

30. Rankin J, Tennant PW, Stothard KJ, Bythell M, Summerbell CD, Bell R. Maternal body mass index and congenital

anomaly risk: a cohort study. Int J Obes (Lond) 2010 Sep;34(9):1371-80.

31. Watkins ML, Rasmussen SA, Honein MA, Botto LD, Moore CA. Maternal obesity and risk for birth defects.

Pediatrics 2003 May;111(5 Pt 2):1152-8.

32. Persson M, Razaz N, Edstedt Bonamy AK, Villamor E, Cnattingius S. Maternal Overweight and Obesity and Risk of

Congenital Heart Defects. J Am Coll Cardiol 2019 Jan 8;73(1):44-53.

33. Best KE, Tennant PW, Bell R, Rankin J. Impact of maternal body mass index on the antenatal detection of

congenital anomalies. BJOG 2012 Nov;119(12):1503-11.

34. Uhden M, Knippel AJ, Stressig R, Hammer R, Siegmann H, Froehlich S, et al. Impact of maternal obesity and

maternal overweight on the detection rate of fetal heart defects and the image quality of prenatal echocardiography.

Ultraschall Med 2011 Dec;32 Suppl 2:E108-14.

35. Block SR, Watkins SM, Salemi JL, Rutkowski R, Tanner JP, Correia JA, et al. Maternal pre-pregnancy body mass

index and risk of selected birth defects: evidence of a dose-response relationship. Paediatr Perinat Epidemiol 2013

Nov;27(6):521-31.

36. Agopian AJ, Moulik M, Gupta-Malhotra M, Marengo LK, Mitchell LE. Descriptive epidemiology of non-syndromic

complete atrioventricular canal defects. Paediatr Perinat Epidemiol 2012 Nov;26(6):515-24.

37. Boyd HA, Basit S, Behrens I, Leirgul E, Bundgaard H, Wohlfahrt J, et al. Association Between Fetal Congenital Heart

Defects and Maternal Risk of Hypertensive Disorders of Pregnancy in the Same Pregnancy and Across Pregnancies.

Circulation 2017 Jul 4;136(1):39-48.

38. Chaithra S, Agarwala S, Ramachandra NB. High-risk genes involved in common septal defects of congenital heart

disease. Gene 2022 Oct 5;840:146745.

39. Wiegering A, Ruther U, Gerhardt C. The Role of Hedgehog Signalling in the Formation of the Ventricular Septum. J

Dev Biol 2017 Dec 12;5(4).

40. Bruneau BG. The developmental genetics of congenital heart disease. Nature 2008 Feb 21;451(7181):943-8.

41. Diab NS, Barish S, Dong W, Zhao S, Allington G, Yu X, et al. Molecular Genetics and Complex Inheritance of

Congenital Heart Disease. Genes (Basel) 2021 Jun 30;12(7).

42. Chapman G, Moreau JLM, I PE, Szot JO, Iyer KR, Shi H, et al. Functional genomics and gene-environment

interaction highlight the complexity of congenital heart disease caused by Notch pathway variants. Hum Mol Genet

2020 Mar 13;29(4):566-79.

43. Oyen N, Diaz LJ, Leirgul E, Boyd HA, Priest J, Mathiesen ER, et al. Prepregnancy Diabetes and Offspring Risk of

Congenital Heart Disease: A Nationwide Cohort Study. Circulation 2016 Jun 7;133(23):2243-53.

44. Klena NT, Gibbs BC, Lo CW. Cilia and Ciliopathies in Congenital Heart Disease. Cold Spring Harb Perspect Biol 2017

Aug 1;9(8).

45. Li Y, Klena NT, Gabriel GC, Liu X, Kim AJ, Lemke K, et al. Global genetic analysis in mice unveils central role for cilia

in congenital heart disease. Nature 2015 May 28;521(7553):520-4.

46. Hildebrandt F, Benzing T, Katsanis N. Ciliopathies. N Engl J Med 2011 Apr 21;364(16):1533-43.

47. Vaisse C, Reiter JF, Berbari NF. Cilia and Obesity. Cold Spring Harb Perspect Biol 2017 Jul 5;9(7).

48. Davenport JR, Watts AJ, Roper VC, Croyle MJ, van Groen T, Wyss JM, et al. Disruption of intraflagellar transport in

adult mice leads to obesity and slow-onset cystic kidney disease. Curr Biol 2007 Sep 18;17(18):1586-94.

49. Hearn T. ALMS1 and Alstrom syndrome: a recessive form of metabolic, neurosensory and cardiac deficits. J Mol

Med (Berl) 2019 Jan;97(1):1-17.

50. Gerhardt C, Lier JM, Kuschel S, Ruther U. The ciliary protein Ftm is required for ventricular wall and septal

development. PLoS ONE 2013;8(2):e57545.

Table 1. Maternal, pregnancy and offspring characteristics in singleton pregnancies in Denmark 2008-2018

	Pregnancies with any congenital heart defects (EUROCAT)	Severe congenital heart defects (EUROCAT)	Pregnancies without congenital heart defects
	n	n	n
Total	5 498	1 227	541 680
	n (%)	n (%)	n (%)
Body mass index, kg/m2			
< 18.5	371 (6.8)	79 (6.4)	35 792 (6.6)
18.5-<25	2 968 (54.0)	656 (53.5)	318 498 (58.8)
25-<30	1 299 (23.6)	289 (23.6)	117 372 (21.7)
30-<35	531 (9.7)	123 (10.0)	45 927 (8.5)
35-<40	203 (3.7)	53 (4.3)	16 633 (3.1)
≥40	126 (2.3)	27 (2.2)	7 458 (1.4)
Maternal age at conception, years			
<20	125 (2.3)	31 (2.5)	9 371 (1.7)
20-24	773 (14.1)	174 (14.2)	70 701 (13.1)
25-29	1 871 (34.0)	404 (32.9)	184 442 (34.1)
30-34	1 745 (31.7)	403 (32.8)	181 879 (33.6)
35-39	843 (15.3)	188 (15.3)	81 370 (15.0)
≥40	141 (2.6)	27 (2.2)	13 917 (2.8)
Ethnicity			
Nordic	5 056 (92.0)	1 134 (92.4)	492 378 (90.9)
Non-Nordic	315 (5.7)	73 (5.9)	35 846 (6.6)
Missing	127 (2.3)	20 (1.6)	13 456 (2.5)
Smoking status			
No	4 724 (85.9)	1 080 (88.0)	478 823 (88.4)
Yes	627 (11.4)	115 (9.4)	50 238 (9.3)
Stopped	92 (1.7)	20 (1.6)	8 765 (1.6)
Missing	55 (1.0)	12 (1.0)	3 854 (0.7)
Conception			
Spontaneous	4 950 (90.0)	1 117 (91.0)	497 936 (91.9)
Assisted	463 (8.4)	97 (7.9)	36 516 (6.8)
Unknown	85 (1.5)	13 (1.1)	7 228 (1.3)
Parity			
0	2 046 (37.2)	416 (33.9)	181 065 (33.4)
1	1 571 (28.6)	367 (29.9)	153 479 (28.3)
2	540 (9.8)	133 (10.8)	53 959 (10.0)
≥3	203 (3.7)	38 (3.1)	16 653 (3.1)
Missing	1 138 (20.7)	273 (22.2)	136 524 (25.2)
Year of estimated due date			

2008	216 (3.9)	57 (4.6)	25 266 (4.7)
2009	477 (8.7)	126 (10.3)	56 468 (10.4)
2010	550 (10.0)	131 (10.7)	57 687 (10.7)
2011	528 (9.7)	120 (9.8)	53 630 (9.9)
2012	534 (9.7)	137 (11.2)	53 512 (9.9)
2013	508 (9.2)	120 (9.8)	51 331 (9.5)
2014	590 (10.7)	141 (11.5)	52 609 (9.7)
2015	642 (11.7)	137 (11.2)	54 215 (10.0)
2016	607 (11.0)	110 (9.0)	57 402 (10.6)
2017	543 (9.9)	101 (8.2)	56 569 (10.4)
2018	303 (5.5)	47 (3.8)	22 991 (4.2)
Outcome pregnancy			
Live births	5 187 (94.3)	1 011 (82.4)	529 291 (97.7)
Stillbirths	41 (0.7)	26 (2.1)	1 582 (0.3)
Abortions incl. terminated pregnancies	245 (4.5)	175 (14.3)	4 828 (0.9)
Missing	25 (0.5)	15 (1.2)	5 979 (1.1)
Offspring sex			
Male	2 771 (50.4)	624 (50.9)	271 571 (50.1)
Female	2 416 (43.9)	387 (31.5)	257 720 (47.6)
Unknown	311 (5.7)	216 (17.6)	12 389 (2.3)

339   Abbreviations: EUROCAT, European Surveillance of Congenital Anomalies (diagnoses listed in Table S1)

340   Table 2. Relative risks of congenital heart defects by maternal body mass index in 547 178 offspring (live births,

341   stillbirths, abortions and terminated pregnancies), Denmark 2008-2018

	No CHDs	CHDs						Severe CHDs				
	n = 541 680	n = 5 498						n = 1 227				
Maternal BMI (kg/m2)	Total	Total	Crude RR	95% CI	aRR*	95% CI	Total	Crude RR	95% CI	aRR*	95% CI
< 18.5	35 800	371	1.11	1.00-1.24	1.07	0.95-1.19	79	1.07	0.84-1.34	1.02	0.79-1.30
18.5 - 24.9	318 489	2 968	1.00	ref	1.00	ref	656	1.00	ref	1.00	ref
25 - 29.9	117 373	1 299	1.19	1.11-1.27	1.17	1.09-1.25	289	1.19	1.04-1.37	1.20	1.04-1.38
30 - 34.9	45 926	531	1.24	1.13-1.36	1.23	1.12-1.36	123	1.30	1.07-1.57	1.28	1.04-1.56
35 - 39.9	16 635	203	1.31	1.13-1.50	1.26	1.09-1.46	53	1.55	1.15-2.02	1.47	1.09-1.96
≥ 40	7 457	126	1.80	1.50-2.14	1.81	1.50-2.15	27	1.76	1.17-2.52	1.85	1.23-2.67

Abbreviations: aRR, adjusted relative risk; BMI, body mass index; CHD, congenital heart defects; CI, confidence

interval; RR, relative risk.

*aRR adjusted for maternal age at conception, smoking status (yes/no/stopped) and year of estimated due date

comparing CHD risk in women with early-pregnancy BMI < 18.5 kg/m^2 or BMI ≥ 25 kg/m^2 with women with early-

pregnancy normal BMI (18.5-24.9 kg/m^2).

Table 3. Relative risks of congenital heart defects in second pregnancy by interpregnancy maternal body mass index

changes in 107 627 women with two consequtive singleton pregnancies, Denmark 2008-2018.

BMI change from 1st to 2nd pregnancy		1st pregnancy	2nd pregnancy	Risk of CHDs in 2nd pregnancy					
Units, kg/m2	No. of women with 1st and 2nd pregnancy (%)	Mean BMI	Mean BMI	n/N	CHDs (%)	Crude RR	95% CI	aRR*	95% CI
<-2	5 941 (5.5)	27.3	24.3	50/5 891	0.8	0.95	0.70-1.26	0.84	0.61-1.12
-2 to <-1	11 154 (10.4)	24.2	22.8	90/11 064	0.8	0.91	0.72-1.14	0.88	0.70-1.09
-1 to <1	54 154 (50.3)	22.8	22.9	479/53 675	0.9	1.00	ref	1.00	ref
1 to <2	16 940 (15.7)	23.8	25.2	156/16 784	0.9	1.04	0.87-1.24	1.01	0.84-1.21
2 to <4	14 010 (13.0)	25.0	27.8	155/13 855	1.1	1.25	1.04-1.50	1.17	0.97-1.40
≥ 4	5 428 (5.0)	26.3	31.4	68/5 360	1.3	1.42	1.09-1.81	1.27	0.96-1.64
Total	107 627	24.9	25.8		1.0				

Abbreviations: aRR, adjusted relative risk; BMI, body mass index; CHDs, congenital heart defects; CI, confidence

interval; n, number of women with their first pregnancy without CHDs and second pregnancy with CHDs in the

offspring; N, number of women with first and second pregnancies without CHDs; RR, relative risk.

*aRR adjusted for maternal age at conception at second pregnancy and early-pregnancy BMI at 1st pregnancy.

Figure 1. Flowchart

Abbreviations: BMI, body mass index; CHDs, congenital heart defects

Figure 2. Crude relative risks for five subtypes of congenital heart defects by maternal body mass index, singleton

pregnancies in Denmark 2008-2018

Body mass index 18.5-24.9 kg/m^2 was considered as the normal range and used as a reference.

Abbreviations: CHDs, congenital heart defects; CI, confidence interval; RR, relative risk; N, number of events